Enovis Corporation Common Stock (ENOV)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, consistent earnings, and a margin of safety. Enovis is a medical technology company with prevention and recovery and reconstructive segments, and its revenue base is real: FY2023 revenue was $1.7B, FY2024 was $2.1B, and FY2025 was $2.2B, with FairStock showing 5.43% revenue growth. But the earnings record is poor. It lost money in each of the last four years, including FY2025 net loss of $1.2B and FY2024 net loss of $825.5M. The latest fiscal Q2 2026, quarter ended 2026-07-03, showed revenue of $582.8M and a net loss of $1.2M, or diluted EPS of $-0.02, a big improvement from fiscal Q2 2025's $36.7M net loss. Still, FairStock's P/E is -0.99, ROE is -54.14%, ROCE is 1.20%, and D/E is 0.93. The Altman Z-Score of 0.10 suggests distress risk, and the Piotroski F-Score of 5/9 is only middling. The positive is FCF: $63.7M trailing, a 5.8% FCF yield, and the stock at $18.99 on 2026-10-13 trades at 0.74 times book value. Graham would ask for proven earning power; Enovis does not yet have it. Buffett would ask whether the bracing and reconstructive products have a moat; the losses imply no clear pricing power. So this is a cheap-looking asset with unproven economics. If losses keep shrinking, value could emerge. If not, book value and cash flow may not protect investors.

In plain English: Enovis makes medical devices and orthopedic products used for prevention, recovery, and reconstruction. The business still loses money and has not earned a full-year profit in recent years, although the latest quarter was close to break-even. At $18.99, the shares look inexpensive compared with the company's net asset value, but weak profits mean the price is not clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-07-03) · fiscal Q1 2026 10-Q (period ended 2026-04-03) · fiscal Q3 2025 10-Q (period ended 2025-10-03) · fiscal Q2 2025 10-Q (period ended 2025-07-04) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer